|
Main
|
|
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
|
Register:
|
ClinicalTrials.gov |
|
Last refreshed on:
|
22 May 2023 |
|
Main ID: |
NCT02748434 |
|
Date of registration:
|
20/04/2016 |
|
Prospective Registration:
|
Yes |
|
Primary sponsor: |
|
|
Public title:
|
Glucose Variability in Subclinical Hypertrophy
|
|
Scientific title:
|
Glucose Variability in Subclinical Hypertrophy |
|
Date of first enrolment:
|
October 2016 |
|
Target sample size:
|
9 |
|
Recruitment status: |
Active, not recruiting |
|
URL:
|
https://clinicaltrials.gov/show/NCT02748434 |
|
Study type:
|
Interventional |
|
Study design:
|
Allocation: Randomized. Intervention model: Crossover Assignment. Primary purpose: Other. Masking: Single (Outcomes Assessor).
|
|
Phase:
|
N/A
|
|
|
Countries of recruitment
|
|
Canada
| | | | | | | |
|
Contacts
|
|
Name:
|
Jordanna Kapeluto, MD |
|
Address:
|
|
|
Telephone:
|
|
|
Email:
|
|
|
Affiliation:
|
University of British Columbia |
|
|
Name:
|
Graydon Meneilly, MD |
|
Address:
|
|
|
Telephone:
|
|
|
Email:
|
|
|
Affiliation:
|
University of British Columbia |
|
|
Name:
|
Breay Paty, MD |
|
Address:
|
|
|
Telephone:
|
|
|
Email:
|
|
|
Affiliation:
|
University of British Columbia |
|
|
Key inclusion & exclusion criteria
|
Inclusion Criteria:
- Participation in phase 1
- Type 1 or Type 2 diabetes for at least 2 years
- Using insulin to manage diabetes
- At least 19 years of age
Exclusion Criteria:
- Taking insulin secretagogues (gliclazide, glyburide, glipizide
- Taking other injectable diabetes medications (i.e. liraglutide, Victoza)
- Taking systemic steroids (e.g. prednisone)
- Not fluent in speaking and writing English (unless accompanied by a translator)
Age minimum:
19 Years
Age maximum:
N/A
Gender:
All
|
|
Health Condition(s) or Problem(s) studied
|
|
Diabetes Mellitus
|
|
Lipohypertrophy
|
|
Intervention(s)
|
|
Other: Lipohypertrophy
|
|
Other: Normal Subcutaneous Tissue
|
|
Primary Outcome(s)
|
|
Blood glucose levels
[Time Frame: Continuously for 12 days]
|
|
Secondary ID(s)
|
|
H16-01025
|
|
Source(s) of Monetary Support
|
|
Please refer to primary and secondary sponsors
|
|
Results
|
|
Results available:
|
|
|
Date Posted:
|
|
|
Date Completed:
|
|
|
URL:
|
|
|
|